{
    "clinical_study": {
        "@rank": "31877", 
        "acronym": "AflibxMyopia", 
        "arm_group": {
            "arm_group_label": "Aflibercept injection", 
            "arm_group_type": "Experimental", 
            "description": "Myopic eyes with retinal neovascularization submitted a aflibercept intravitreal injection"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the clinical results of anti-VEGF intra-vitreal\n      injections (IVT) in CNV secondary"
        }, 
        "brief_title": "Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Choroidal Retinal Neovascularization", 
        "condition_browse": {
            "mesh_term": [
                "Neovascularization, Pathologic", 
                "Retinal Neovascularization", 
                "Choroidal Neovascularization"
            ]
        }, 
        "detailed_description": {
            "textblock": "Twenty consecutive patients (30 eyes) with subfoveal PM-CNV, 9 of whom had been\n      unsuccessfully treated with Visudyne PDT, were treated with IVT of 0.5mg ranibizumab. ETDRS\n      best corrected visual acuity, macular thickness on OCT scans, and angiographic features were\n      recorded and evaluated. The aspect of OCT scans passing across the PM-CNV was also analyzed.\n      IVTs were repeated only in case of persistent angiographic leakage and if OCT scans showed\n      retinal thickening or edema and serous retinal detachment. The follow-up period was at least\n      6 months"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Myopic and CNVM\n\n        Exclusion Criteria:\n\n          -  Patients with poor compliance\n\n          -  Patients with uncontrolled diabetes and hypertension or any other medical condition\n             that increase the risk of complications like recent history of Stroke or myocardial\n             infraction (< one year). (Physician clearance was obtained for all patients).\n\n          -  Age related macular degeneration with Juxtafoveal and Subfoveal CNVM:    Recurrent\n             CNVM following PDT and TTT with IVTA. Patient who could not afford PDT, Macugen or\n             Lucentis which is FDA approved.\n\n          -  Patients who had undergone major surgery 28 days before, were excluded from the study\n             and it was also suspended prior to elective surgery.\n\n          -  Refractory macular oedema due to vein occlusion, Pseudophakia, Clinically significant\n             macular oedema (CSME) etc. that affects vision and does not respond adequately to\n             usual treatment methods.\n\n          -  Proliferative diabetic retinopathy, non-resolving vitreous haemorrhage with PDR.\n\n          -  Idiopathic CNVM, Inflammatory CNVM and other conditions associated with CNVM."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02033018", 
            "org_study_id": "JJ - 3/2013"
        }, 
        "intervention": {
            "arm_group_label": "Aflibercept injection", 
            "description": "Aflibercept intravitreal injection", 
            "intervention_name": "Aflibercept Injection", 
            "intervention_type": "Drug", 
            "other_name": "Aflibercept intravitreal injection of 0,5 mg ( 0.05mL"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Aflibercept", 
            "Myopia", 
            "Complications", 
            "Neovascularization", 
            "OCT"
        ], 
        "lastchanged_date": "January 9, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Goiania", 
                        "country": "Brazil", 
                        "state": "GO", 
                        "zip": "74120-050"
                    }, 
                    "name": "Instituto de Olhos de Goiania"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Raquel Monteiro", 
                    "phone": "55 62 3220 2511"
                }, 
                "contact_backup": {
                    "email": "nassaral@terra.com.br", 
                    "last_name": "Jo\u00e3o J Nassaralla, JR", 
                    "phone": "55 62 3220 2545"
                }, 
                "facility": {
                    "address": {
                        "city": "Goiania", 
                        "country": "Brazil", 
                        "state": "GO", 
                        "zip": "74120-050"
                    }, 
                    "name": "Instituto de Olhos de Goiania"
                }, 
                "investigator": {
                    "last_name": "Joao J Nassaralla, Jr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "1", 
        "official_title": "Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization", 
        "overall_contact": {
            "last_name": "Raquel Monteiro", 
            "phone": "55 62 3220 2500"
        }, 
        "overall_contact_backup": {
            "email": "nassaral@terra.com.br", 
            "last_name": "Jo\u00e3o J Nassaralla, Jr", 
            "phone": "55 62 3220 2545"
        }, 
        "overall_official": {
            "affiliation": "Instituto de Olhos de Goi\u00e2nia", 
            "last_name": "Joao J Nassaralla, Jr", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Health Surveillance Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "8 patients with subfoveal PM-CNV, were treated with of 2 mg ( 0.05mL) RII. ETDRS best corrected visual acuity, macular thickness on OCT scans, and angiographic features were recorded and evaluated. The aspect of OCT scans passing across the PM-CNV was also analyzed. AII were repeated only in case of persistent angiographic leakage and if OCT scans showed retinal thickening or edema and serous retinal detachment. The follow-up period was at least 1 year.", 
            "measure": "Efficacy", 
            "safety_issue": "Yes", 
            "time_frame": "To evaluate the clinical results of aflibercept intravitreal injection (AII) in choroidal neovascularization (CNV) secondary to pathologic myopia (PM-CNV), after 1 year follow up."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02033018"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "8 patients with subfoveal PM-CNV, were treated with of 2 mg ( 0.05mL) RII. ETDRS best corrected visual acuity, macular thickness on OCT scans, and angiographic features were recorded and evaluated. The aspect of OCT scans passing across the PM-CNV was also analyzed.", 
            "measure": "Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "To evaluate the clinical results of aflibercept intravitreal injection (AII) in choroidal neovascularization (CNV) secondary to pathologic myopia (PM-CNV), after 1 year follow up."
        }, 
        "source": "Instituto de Olhos de Goiania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Instituto de Olhos de Goiania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}